Cargando…

LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells

OBJECTIVE: Endothelial cell (EC) activation facilitates leukocyte adhesion to vascular walls, which is implicated in a variety of cardiovascular diseases and is a target for prevention and treatment. Despite the development of anti-inflammatory medications, cost-effective therapies with significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Angom, Ramcharan Singh, Zhu, Jian, Wu, Alexander T H, Sumitra, Maryam Rachmawati, Pham, Victoria, Dutta, Shamit, Wang, Enfeng, Madamsetty, Vijay Sagar, Perez-Cordero, Gabriel D, Huang, Hsu-Shan, Mukhopadhyay, Debabrata, Wang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436973/
https://www.ncbi.nlm.nih.gov/pubmed/34526801
http://dx.doi.org/10.2147/JIR.S305168
_version_ 1783752086821797888
author Angom, Ramcharan Singh
Zhu, Jian
Wu, Alexander T H
Sumitra, Maryam Rachmawati
Pham, Victoria
Dutta, Shamit
Wang, Enfeng
Madamsetty, Vijay Sagar
Perez-Cordero, Gabriel D
Huang, Hsu-Shan
Mukhopadhyay, Debabrata
Wang, Ying
author_facet Angom, Ramcharan Singh
Zhu, Jian
Wu, Alexander T H
Sumitra, Maryam Rachmawati
Pham, Victoria
Dutta, Shamit
Wang, Enfeng
Madamsetty, Vijay Sagar
Perez-Cordero, Gabriel D
Huang, Hsu-Shan
Mukhopadhyay, Debabrata
Wang, Ying
author_sort Angom, Ramcharan Singh
collection PubMed
description OBJECTIVE: Endothelial cell (EC) activation facilitates leukocyte adhesion to vascular walls, which is implicated in a variety of cardiovascular diseases and is a target for prevention and treatment. Despite the development of anti-inflammatory medications, cost-effective therapies with significant anti-inflammatory effects and lower organ toxicity remain elusive. The goal of this study is to identify novel synthetic compounds that inhibit EC inflammatory response with minimal organ toxicity. METHODS AND RESULTS: In this study, we discovered LCC-09, a salicylanilide derivative consisting of the functional fragment of magnolol, 2,4-difluorophenyl, and paeonol moiety of salicylate, as a novel anti-inflammatory compound in cultured ECs and zebrafish model. LCC-09 was shown to inhibit pro-inflammatory cytokine tumor necrosis factor-α (TNFα)-induced expression of adhesion molecules and inflammatory cytokines, leading to reduced leukocyte adhesion to ECs. Mechanistically, LCC-09 inhibits the phosphorylation of signal transducer and activator of transcription 1 (STAT1), TNFα-induced degradation of NF-κ-B Inhibitor-α (IκBα) and phosphorylation of NFκB p65, resulting in reduced NFκB transactivation activity and binding to E-selectin promoter. Additionally, LCC-09 attenuated TNFα-induced generation of reactive oxygen species in ECs. Molecular docking models suggest the binding of LCC-09 to NFκB essential modulator (NEMO) and Janus tyrosine kinase (JAK) may lead to dual inhibition of NFκB and STAT1. Furthermore, the anti-inflammatory effect of LCC-09 was validated in the lipopolysaccharides (LPS)-induced inflammation model in zebrafish. Our results demonstrated that LCC-09 significantly reduced the LPS-induced leukocyte recruitment and mortality of zebrafish embryos. Finally, LCC-09 was administered to cultured ECs and zebrafish embryos and showed minimal toxicities. CONCLUSION: Our results support that LCC-09 inhibits EC inflammatory response but does not elicit significant toxicity.
format Online
Article
Text
id pubmed-8436973
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84369732021-09-14 LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells Angom, Ramcharan Singh Zhu, Jian Wu, Alexander T H Sumitra, Maryam Rachmawati Pham, Victoria Dutta, Shamit Wang, Enfeng Madamsetty, Vijay Sagar Perez-Cordero, Gabriel D Huang, Hsu-Shan Mukhopadhyay, Debabrata Wang, Ying J Inflamm Res Original Research OBJECTIVE: Endothelial cell (EC) activation facilitates leukocyte adhesion to vascular walls, which is implicated in a variety of cardiovascular diseases and is a target for prevention and treatment. Despite the development of anti-inflammatory medications, cost-effective therapies with significant anti-inflammatory effects and lower organ toxicity remain elusive. The goal of this study is to identify novel synthetic compounds that inhibit EC inflammatory response with minimal organ toxicity. METHODS AND RESULTS: In this study, we discovered LCC-09, a salicylanilide derivative consisting of the functional fragment of magnolol, 2,4-difluorophenyl, and paeonol moiety of salicylate, as a novel anti-inflammatory compound in cultured ECs and zebrafish model. LCC-09 was shown to inhibit pro-inflammatory cytokine tumor necrosis factor-α (TNFα)-induced expression of adhesion molecules and inflammatory cytokines, leading to reduced leukocyte adhesion to ECs. Mechanistically, LCC-09 inhibits the phosphorylation of signal transducer and activator of transcription 1 (STAT1), TNFα-induced degradation of NF-κ-B Inhibitor-α (IκBα) and phosphorylation of NFκB p65, resulting in reduced NFκB transactivation activity and binding to E-selectin promoter. Additionally, LCC-09 attenuated TNFα-induced generation of reactive oxygen species in ECs. Molecular docking models suggest the binding of LCC-09 to NFκB essential modulator (NEMO) and Janus tyrosine kinase (JAK) may lead to dual inhibition of NFκB and STAT1. Furthermore, the anti-inflammatory effect of LCC-09 was validated in the lipopolysaccharides (LPS)-induced inflammation model in zebrafish. Our results demonstrated that LCC-09 significantly reduced the LPS-induced leukocyte recruitment and mortality of zebrafish embryos. Finally, LCC-09 was administered to cultured ECs and zebrafish embryos and showed minimal toxicities. CONCLUSION: Our results support that LCC-09 inhibits EC inflammatory response but does not elicit significant toxicity. Dove 2021-09-08 /pmc/articles/PMC8436973/ /pubmed/34526801 http://dx.doi.org/10.2147/JIR.S305168 Text en © 2021 Angom et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Angom, Ramcharan Singh
Zhu, Jian
Wu, Alexander T H
Sumitra, Maryam Rachmawati
Pham, Victoria
Dutta, Shamit
Wang, Enfeng
Madamsetty, Vijay Sagar
Perez-Cordero, Gabriel D
Huang, Hsu-Shan
Mukhopadhyay, Debabrata
Wang, Ying
LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells
title LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells
title_full LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells
title_fullStr LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells
title_full_unstemmed LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells
title_short LCC-09, a Novel Salicylanilide Derivative, Exerts Anti-Inflammatory Effect in Vascular Endothelial Cells
title_sort lcc-09, a novel salicylanilide derivative, exerts anti-inflammatory effect in vascular endothelial cells
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436973/
https://www.ncbi.nlm.nih.gov/pubmed/34526801
http://dx.doi.org/10.2147/JIR.S305168
work_keys_str_mv AT angomramcharansingh lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT zhujian lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT wualexanderth lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT sumitramaryamrachmawati lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT phamvictoria lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT duttashamit lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT wangenfeng lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT madamsettyvijaysagar lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT perezcorderogabrield lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT huanghsushan lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT mukhopadhyaydebabrata lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells
AT wangying lcc09anovelsalicylanilidederivativeexertsantiinflammatoryeffectinvascularendothelialcells